BioSpecifics announces initiation of Phase II trial for canine lipomas

BioSpecifics announced that it has initiated a placebo controlled randomized Phase II clinical trial, Chien-804, to evaluate the efficacy of XIAFLEX for canines with benign subcutaneous lipomas. Canine lipomas are encapsulated fat deposits that occur under the skin and affect 1.7M dogs in the U.S. BioSpecifics anticipates that it will complete this study in the first half 2013.

View Comments (0)